Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Agios Pharma (DE:8AP)
FRANKFURT:8AP
Agios Pharma (8AP) Stock Price & Analysis
0 Followers
8AP Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€18.80 - €32.20
Previous Close€32.2
Volume0.00
Average Volume (3M)155.00
Market Cap
€1.82B
Enterprise Value€1.16B
Total Cash (Recent Filing)$776.93M
Total Debt (Recent Filing)$72.00M
Price to Earnings (P/E)N/A
Beta0.34
Next Earnings
Aug 01, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding56,772,966
10 Day Avg. Volume0
30 Day Avg. Volume155
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.42
Price to Sales (P/S)68.15
Price to Cash Flow (P/CF)-6.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue43.34
Enterprise Value/Gross Profit48.56
Enterprise Value/Ebitda-3.42
Forecast
1Y Price Target
€40.42Price Target Upside25.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Agios Pharma News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe primary endpoint for the ENERGIZE-T trial is innovative, focusing on a 50% transfusion burden reduction, potentially offering a better reflection of patient experiences.
Market ExpansionThe company has seen a steady increase in the number of patients completing prescription enrollment forms, indicating growing patient engagement and potential market expansion.
Regulatory MilestonesManagement plans to submit regulatory filings based on positive ENERGIZE and ENERGIZE-T results, aiming for a broad thalassemia label.
Bears Say
EarningsPyrukynd sales of $7.1mn missed consensus by approximately 10%, indicating a decline in revenue.
Quarterly ResultsAGIO reported Q4 results with Pyrukynd sales below expectations and a significant net loss.
Sales PerformanceThe company attributed the lower sales to reduced customer inventory levels, suggesting potential issues in product demand or supply chain management.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
1.36% Other Institutional Investors
98.64% Public Companies and
Individual Investors
8AP FAQ
What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest stock price was €18.80 and its highest was €32.20 in the past 12 months.
What is Agios Pharma’s market cap?
Currently, no data Available
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s upcoming earnings report date is Aug 01, 2024 which is in 88 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on May 02, 2024. The company reported -€1.353 earnings per share for the quarter, beating the consensus estimate of -€1.538 by €0.185.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma does not currently pay dividends.
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Agios Pharma have?
Currently, no data Available
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of -€1.353 in its last earnings report, beating expectations of -€1.538. Following the earnings report the stock price went up 2.614%.
Which hedge fund is a major shareholder of Agios Pharma?
Among the largest hedge funds holding Agios Pharma’s share is Farallon Capital Management, L.L.C.. It holds Agios Pharma’s shares valued at 93M.
---
Agios Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€40.42 (25.53% Upside)
€40.42 (25.53% Upside)
Blogger Sentiment
Bullish
DE:8AP Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $4.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.02%
12-Months-Change
Fundamentals
Return on Equity
-39.61%
Trailing 12-Months
Asset Growth
-26.20%
Trailing 12-Months
Company Description
Agios Pharma
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
---
8AP Company Deck
---
8AP Earnings Call
Q1 2024
0:00 / 0:00
---
8AP Stock 12 Months Forecast
Average Price Target
€40.42
▲(25.53% Upside)
Technical Analysis
Agios Pharma
―
Crispr Therapeutics AG
―
Bluebird Bio
―
Crinetics Pharmaceuticals
―
Nektar Therapeutics
―
Best Analysts Covering 8AP
1 Year
1 Year Success Rate
7/9 ratings generated profit
1 Year Average Return
+27.31%
reiterated a buy rating 3 months ago
Copying Greg Harrison's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +27.31% per trade.
---